Cervical Cancer Cell Line Xenograft Models

Introduction to Cell Line Xenograft Models

CDX models are established by implanting human cancer cell lines into immunocompromised mice. These cell lines, often derived from cervical cancer, such as the widely recognized HeLa cell line, create a simulated environment that mirrors tumor biological behavior. This allows researchers to investigate tumor growth, metastasis, drug sensitivity, and therapeutic effectiveness on a dedicated experimental platform.

Fig. 1 Tumor implantation process in cell line-derived xenograft (CDX) models.(Khairani AF, et al., 2025)

Characteristics of Cervical Cancer CDX Models

• High Tumor Formation Rate: They achieve a high success rate in tumor engraftment, facilitating consistent study outcomes.
• Short Modeling Time: CDX models can be developed quickly, allowing for timely results and efficient progression in research.
• Good Reproducibility: These models maintain consistent growth patterns, ensuring reliable and comparable data.
• Versatile Inoculation Methods: They support various inoculation techniques, including subcutaneous and orthotopic, to suit specific study requirements.
• Diverse Cell Line Availability: A wide range of cervical cancer cell lines enhances flexibility for different experimental needs.

Our Services

Creation of cervical cancer CDX models typically involves injecting cervical cancer cell lines into the target area of immunodeficient mice (e.g., nude or SCID mice) via subcutaneous, intraperitoneal, intramuscular, and intravenous injections.

Antitumor Drug Screening and Efficacy Assessment

• Chemotherapy/Targeted Drug Testing
  Evaluate the effects of chemotherapy agents (e.g., cisplatin) and targeted therapies using CDX models with cervical cancer cell lines, implanted subcutaneously or in situ.
• Combination Therapy Development
  Test the synergistic effects of immune checkpoint inhibitors (e.g., PD-1 antibodies) alongside other treatments.

Immunotherapy Mechanism Research

• CAR-T Therapy Validation
  Use CDX models that express HPV E6/E7 antigens to study CAR-T cell efficacy and escape mechanisms.
• Microenvironment Simulation
  Partially simulate immune responses in immunodeficient models by using humanized mice.

Gene Function and Molecular Mechanism Exploration

• Epigenetic Regulation
• Pathway Validation
  Analyze how HPV oncogenes regulate tumor growth using CDX models with siRNA/shRNA-transfected cells.

Biomarker Discovery and Personalized Treatment Prediction

• Drug Sensitivity Screening
  Use CDX models from various cervical cancer cell lines to identify biomarkers for drug sensitivity (e.g., paclitaxel).
• Methylation Biomarkers
  Assess the correlation between CDX2 methylation levels and clinical TNM staging.

Alfa Cytology is your ideal partner for developing cervical cancer CDX models, backed by our extensive oncology research expertise. We offer ready-to-use models, customizable options, and collaborative R&D services tailored to your needs. From solutions to reports, we provide comprehensive support. Contact us with inquiries or for custom model development.

For research use only.